Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZS805 for Fabry Disease (Phase I/II, China)
ChiCTR2400094356Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZS805 in Fabry disease (FD) (3 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and Tolerability. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ZS805
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on ChiCTR2400094356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094356.